Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $67.06, for a total value of $201,180.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

James J. Vaughn also recently made the following trade(s):

  • On Thursday, December 6th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The shares were sold at an average price of $75.30, for a total value of $225,900.00.
  • On Thursday, November 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The shares were sold at an average price of $85.18, for a total value of $255,540.00.

Genomic Health stock opened at $70.28 on Friday. Genomic Health, Inc. has a 12 month low of $30.04 and a 12 month high of $92.18. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 83.13 and a beta of 0.73.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.28. The business had revenue of $101.30 million for the quarter, compared to analyst estimates of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.06) EPS. As a group, sell-side analysts forecast that Genomic Health, Inc. will post 1.06 earnings per share for the current year.

A number of brokerages recently commented on GHDX. ValuEngine lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 11th. Canaccord Genuity restated a “buy” rating and issued a $82.00 price objective (up previously from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. BidaskClub lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Oppenheimer began coverage on Genomic Health in a research report on Wednesday, December 19th. They issued a “market perform” rating on the stock. Finally, Zacks Investment Research upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $73.00 price objective on the stock in a research report on Tuesday, October 9th. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $58.50.

Several hedge funds have recently made changes to their positions in GHDX. SG Americas Securities LLC acquired a new position in shares of Genomic Health during the 2nd quarter worth approximately $162,000. Pacer Advisors Inc. acquired a new position in shares of Genomic Health during the 3rd quarter worth approximately $171,000. Trexquant Investment LP acquired a new position in shares of Genomic Health during the 3rd quarter worth approximately $202,000. D.A. Davidson & CO. acquired a new position in shares of Genomic Health during the 3rd quarter worth approximately $234,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Genomic Health during the 2nd quarter worth approximately $315,000. 89.14% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Genomic Health, Inc. (GHDX) Insider Sells 3,000 Shares of Stock” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://theolympiareport.com/2019/01/11/insider-selling-genomic-health-inc-ghdx-insider-sells-3000-shares-of-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Story: Penny Stocks, Risk and Reward Factors

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.